Peter Ruane

13.6k total citations · 4 hit papers
78 papers, 4.7k citations indexed

About

Peter Ruane is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Peter Ruane has authored 78 papers receiving a total of 4.7k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Infectious Diseases, 36 papers in Virology and 25 papers in Epidemiology. Recurrent topics in Peter Ruane's work include HIV/AIDS drug development and treatment (48 papers), HIV Research and Treatment (36 papers) and HIV/AIDS Research and Interventions (22 papers). Peter Ruane is often cited by papers focused on HIV/AIDS drug development and treatment (48 papers), HIV Research and Treatment (36 papers) and HIV/AIDS Research and Interventions (22 papers). Peter Ruane collaborates with scholars based in United States, France and United Kingdom. Peter Ruane's co-authors include Edwin DeJesus, Andrew Cheng, Gildon Beall, Daniel Berger, Kitty Yale, Calvin Cohen, Lijie Zhong, Barry Bernstein, Martin King and Eugene Sun and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Peter Ruane

73 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

2002 518 citations Sharon Walmsley, Barry Bernstein et al. New England Journal of Medicine profile →
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

2018 257 citations Rohit Loomba, Zeid Kayali et al. Gastroenterology profile →
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

2021 255 citations Stephen A. Harrison, Peter Ruane et al. profile →
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

2022 164 citations Edwin DeJesus, Hans‐Jürgen Stellbrink et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Ruane United States	32	3.4k	2.2k	1.7k	940	745	78	4.7k
Marc van der Valk Netherlands	39	2.6k 0.8×	1.9k 0.8×	1.6k 1.0×	1.0k 1.1×	1.3k 1.8×	212	4.6k
Daniel Vittecoq France	33	1.9k 0.6×	1.2k 0.5×	1.2k 0.7×	676 0.7×	863 1.2×	144	3.6k
Hiroyuki Gatanaga Japan	36	2.8k 0.8×	2.1k 1.0×	1.5k 0.9×	499 0.5×	646 0.9×	252	4.8k
Stefano Bonora Italy	34	2.5k 0.7×	1.3k 0.6×	962 0.6×	415 0.4×	795 1.1×	223	3.8k
Brian P. Kearney United States	40	3.9k 1.2×	2.4k 1.1×	1.1k 0.7×	698 0.7×	843 1.1×	93	5.1k
David A. Cooper Australia	39	5.5k 1.6×	4.4k 2.0×	1.6k 0.9×	633 0.7×	1.4k 1.9×	118	7.1k
Maria Jesús Pérez‐Elías Spain	29	2.4k 0.7×	1.7k 0.8×	1.1k 0.6×	499 0.5×	786 1.1×	179	3.4k
Schlomo Staszewski Germany	41	6.1k 1.8×	5.1k 2.3×	1.5k 0.9×	378 0.4×	1.6k 2.1×	115	7.3k
Stéphane De Wit Belgium	22	2.5k 0.7×	1.6k 0.7×	1.3k 0.8×	596 0.6×	2.4k 3.3×	66	4.2k
Antonio Di Biagio Italy	26	1.7k 0.5×	984 0.4×	695 0.4×	187 0.2×	709 1.0×	263	2.8k

Countries citing papers authored by Peter Ruane

Since Specialization

Citations

This map shows the geographic impact of Peter Ruane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ruane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ruane more than expected).

Fields of papers citing papers by Peter Ruane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ruane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ruane. The network helps show where Peter Ruane may publish in the future.

Co-authorship network of co-authors of Peter Ruane

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ruane. A scholar is included among the top collaborators of Peter Ruane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ruane. Peter Ruane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hagins, Debbie, Mezgebe Berhe, Gordon Crofoot, et al.. (2025). Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV. AIDS. 40(3). 302–311.

Brar, Indira, Peter Ruane, Mezgebe Berhe, et al.. (2025). Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study. Medicine. 104(8). e41482–e41482.

Colson, Amy E., Peter Ruane, Moti Ramgopal, et al.. (2025). 577. Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir. Open Forum Infectious Diseases. 12(Supplement_1). 2 indexed citations

Gupta, Samir K., Mezgebe Berhe, Gordon Crofoot, et al.. (2022). Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. The Lancet HIV. 10(1). e15–e23. 65 indexed citations

Younossi, Zobair M., Maria Stepanova, Mazen Noureddin, et al.. (2021). Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Hepatology Communications. 5(7). 1201–1211. 24 indexed citations

Brar, Indira, Peter Ruane, Douglas Ward, et al.. (2020). 1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine. Open Forum Infectious Diseases. 7(Supplement_1). S543–S544. 3 indexed citations

Loomba, Rohit, Zeid Kayali, Mazen Noureddin, et al.. (2018). GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 155(5). 1463–1473.e6. 257 indexed citations breakdown →

DeJesus, Edwin, Moti Ramgopal, Gordon Crofoot, et al.. (2017). Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. The Lancet HIV. 4(5). e205–e213. 37 indexed citations

Kwo, Paul Y., Norman Gitlin, Ronald Nahass, et al.. (2016). Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. PMC. 5 indexed citations

10.

Gallant, Joel E., Eric S. Daar, François Raffi, et al.. (2016). Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. The Lancet HIV. 3(4). e158–e165. 127 indexed citations

11.

Palella, Frank J., Martin Fisher, Pablo Tebas, et al.. (2013). Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 28(3). 335–344. 92 indexed citations

12.

Ruane, Peter, Edwin DeJesus, Daniel Berger, et al.. (2013). Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 449–455. 247 indexed citations

13.

Ruane, Peter, et al.. (2010). A 48-Week Pilot Study Switching Suppressed Patients to Darunavir/Ritonavir and Etravirine from Enfuvirtide, Protease Inhibitor(s), and Non-nucleoside Reverse Transcriptase Inhibitor(s). AIDS Research and Human Retroviruses. 26(11). 1215–1219. 3 indexed citations

14.

Lalezari, Jacob, E DeJesus, Olayemi Osiyemi, et al.. (2008). O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults. Journal of the International AIDS Society. 11(S1). 6 indexed citations

15.

Ruane, Peter, Edwin DeJesus, Daniel S Berger, et al.. (2006). Pilot Study of Once-Daily Simplification Therapy with Abacavir/Lamivudine/Zidovudine and Efavirenz for Treatment of HIV-1 Infection. HIV Clinical Trials. 7(5). 229–236. 8 indexed citations

16.

Ruane, Peter & Andrew Luber. (2004). K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.. PubMed. 6(2). 31–31. 9 indexed citations

17.

Eron, Joseph J., Judith Feinberg, Harold A. Kessler, et al.. (2004). Once‐Daily versus Twice‐Daily Lopinavir/Ritonavir in Antiretroviral‐Naive HIV‐Positive Patients: A 48‐Week Randomized Clinical Trial. The Journal of Infectious Diseases. 189(2). 265–272. 104 indexed citations

18.

Walmsley, Sharon, Barry Bernstein, Martin King, et al.. (2002). Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection. New England Journal of Medicine. 346(26). 2039–2046. 518 indexed citations breakdown →

19.

Phillips, Edward H, et al.. (1992). Laparoscopic-Guided Biopsy for Diagnosis of Hepatic Candidiasis. Journal of Laparoendoscopic Surgery. 2(1). 33–38. 8 indexed citations

20.

Ruane, Peter, et al.. (1989). Spirochete-Like Organisms in the Human Gastrointestinal Tract. Clinical Infectious Diseases. 11(2). 184–196. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact